drugset / Trial / NCT01999985
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Phase 1
Completed
25 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim · collabBristol-Myers Squibb · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to: * Find out if the study drugs Afatinib and Dasatinib can be safely given together to patients with lung cancer * Learn how these two drugs work in cancer cells when they are combined * Learn more about the side effects of these two drugs when combined * Find the highest doses of the study drugs Afatinib and Dasatinib that can be given safely without causing serious side effects
Timeline
- Start
- 2013-12-31
- Primary completion
- 2017-03-21
- Completion
- 2019-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 30 mg | — |
| Subject | Afatinib | Small molecule | 40 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | — |